Core Insights - Merck's investigational oral PCSK9 inhibitor, Enlicitide, has shown significant efficacy in reducing LDL-C levels in adults with heterozygous familial hypercholesterolemia (HeFH) during the Phase 3 CORALreef trial [1] Group 1 - Enlicitide demonstrated a significant reduction in LDL-C levels in the trial participants [1] - The Phase 3 CORALreef trial specifically targeted adults diagnosed with HeFH [1] - The results indicate a promising potential for Enlicitide as a treatment option for managing cholesterol levels in this patient population [1]

Core Insights - Merck's investigational oral PCSK9 inhibitor, Enlicitide Decanoate, has shown significant efficacy in reducing LDL-C levels in the Phase 3 CORALreef Lipids trial [1] Company Summary - The trial results indicate that Enlicitide Decanoate effectively lowers LDL-C, which is a critical factor in cardiovascular health [1] - This development positions Merck favorably in the competitive landscape of cholesterol-lowering therapies [1] Industry Summary - The success of Enlicitide Decanoate could impact the broader market for PCSK9 inhibitors, potentially leading to increased adoption of oral therapies over injectable options [1] - The trial results may influence future treatment guidelines and patient management strategies in lipid disorders [1]